<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">ACM</journal-id><journal-title-group><journal-title>Advances in Clinical Medicine</journal-title></journal-title-group><issn pub-type="epub">2161-8712</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.12677/ACM.2020.1011428</article-id><article-id pub-id-type="publisher-id">ACM-38949</article-id><article-categories><subj-group subj-group-type="heading"><subject>ACM20201100000_98822721.pdf</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>医药卫生</subject></subj-group></article-categories><title-group><article-title>
 
 
  伊布替尼单药方案与CHOP方案治疗慢性淋巴细胞白血病的临床疗效观察
  Clinical Efficacy of Ibrutinib Monotherapy and CHOP in the Treatment of Chronic Lymphocytic Leukemia
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>段</surname><given-names>春英</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>吴</surname><given-names>少玲</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>袁</surname><given-names>海峰</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>宋</surname><given-names>峤</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>曹</surname><given-names>正</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib></contrib-group><aff id="aff2"><addr-line>青岛大学医学部，山东 青岛</addr-line></aff><aff id="aff3"><addr-line>青岛大学附属医院血液科，山东 青岛</addr-line></aff><aff id="aff1"><addr-line>null</addr-line></aff><pub-date pub-type="epub"><day>04</day><month>11</month><year>2020</year></pub-date><volume>10</volume><issue>11</issue><fpage>2819</fpage><lpage>2826</lpage><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  
    目的：观察伊布替尼单药方案与CHOP方案治疗初治慢性淋巴细胞白血病的临床疗效及安全性。方法：回顾性分析2014年03月~2020年03月在青岛大学附属医院血液科治疗的48例初治慢性淋巴细胞白血病患者，根据治疗方案不同，将其分为伊布替尼组(30例)及CHOP组(18例)，对比两组治疗方案的临床疗效及不良反应。结果：本研究共纳入48例患者，结果显示伊布替尼组的总有效率(0RR)高于CHOP组(93.33% vs 40.00%)，p &lt; 0.01；伊布替尼组患者1年无进展生存(PFS)率明显高于CHOP组(80.00% vs 33.33%)，差异有统计学意义(P &lt; 0.05)；伊布替尼组患者1年总生存率(OS)为96.67%，而CHOP组为63.33%，差异有统计学意义(P &lt; 0.05)；在接受伊布替尼治疗的患者中，36.67%发生了不良事件，包括出血、房颤、腹泻、感染等；在接受CHOP方案治疗的患者中，有53.33%发生不良反应，包括中性粒细胞减少、贫血、出血和呕吐。结论：伊布替尼治疗初治慢性淋巴细胞白血病患者可达到较高的缓解率，延长无进展生存期，不良反应多为I~II级，较传统化学疗法具有更好的耐受性。
    Objective: To observe the clinical efficacy and safety of ibrutinib single drug regimen and CHOP regimen in the treatment of primary chronic lymphocytic leukemia. Methods: A retrospective analysis was performed on 48 newly treated patients with chronic lymphocytic leukemia who were treated in the hematology department of Qingdao University Hospital from March 2014 to March 2020. According to different treatment regiments, they were divided into ibrutinib group (30 cases) and CHOP group (18 cases). The clinical efficacy and adverse reactions of treatment regiments of the two groups were compared. Results: A total of 48 patients were included in this study. The results showed that the total effective rate (0RR) of the ibrutinib group was higher than that of the CHOP group (93.33% vs 40.00%), P = 0.009. The 1-year progression-free survival (PFS) rate in the ibrutinib group was significantly higher than that in CHOP group (80.00% vs 33.33%), and the difference was statistically significant (P = 0.025). 1-year overall survival (OS) was 96.67% in the ibrutinib group, and 63.33% in CHOP group, with statistically significant differences (P = 0.003). Among patients treated with ibrutinib, 36.67% had adverse events, including bleeding, atrial fibrillation, diarrhea, infection, etc. Adverse reactions, including neutropenia, anemia, bleeding, and vomiting, occurred in 53.33% of patients treated with CHOP. Conclusion: Ibrutinib can achieve higher remission rate and prolong progression free survival time in newly diagnosed patients with chronic lymphoblastic leukemia. The adverse reactions are mostly grade I - II, which is more tolerable than traditional chemotherapy. 
  
 
</p></abstract><kwd-group><kwd>伊布替尼，CHOP，慢性淋巴细胞白血病，有效性，安全性, Brutinib</kwd><kwd> CHOP</kwd><kwd> Chronic Lymphocytic Leukemia</kwd><kwd> Effectiveness</kwd><kwd> Security</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>摘要</title><p>目的：观察伊布替尼单药方案与CHOP方案治疗初治慢性淋巴细胞白血病的临床疗效及安全性。方法：回顾性分析2014年03月~2020年03月在青岛大学附属医院血液科治疗的48例初治慢性淋巴细胞白血病患者，根据治疗方案不同，将其分为伊布替尼组(30例)及CHOP组(18例)，对比两组治疗方案的临床疗效及不良反应。结果：本研究共纳入48例患者，结果显示伊布替尼组的总有效率(0RR)高于CHOP组(93.33% vs 40.00%)，p &lt; 0.01；伊布替尼组患者1年无进展生存(PFS)率明显高于CHOP组(80.00% vs 33.33%)，差异有统计学意义(P &lt; 0.05)；伊布替尼组患者1年总生存率(OS)为96.67%，而CHOP组为63.33%，差异有统计学意义(P &lt; 0.05)；在接受伊布替尼治疗的患者中，36.67%发生了不良事件，包括出血、房颤、腹泻、感染等；在接受CHOP方案治疗的患者中，有53.33%发生不良反应，包括中性粒细胞减少、贫血、出血和呕吐。结论：伊布替尼治疗初治慢性淋巴细胞白血病患者可达到较高的缓解率，延长无进展生存期，不良反应多为I~II级，较传统化学疗法具有更好的耐受性。</p></sec><sec id="s2"><title>关键词</title><p>伊布替尼，CHOP，慢性淋巴细胞白血病，有效性，安全性</p></sec><sec id="s3"><title>Clinical Efficacy of Ibrutinib Monotherapy and CHOP in the Treatment of Chronic Lymphocytic Leukemia<sup> </sup></title><p>Chunying Duan<sup>1</sup>, Shaoling Wu<sup>2*</sup>, Haifeng Yuan<sup>1</sup>, Qiao Song<sup>1</sup>, Zheng Cao<sup>1</sup></p><p><sup>1</sup>Department of Medicine, Qingdao University, Qingdao Shandong</p><p><sup>2</sup>Department of Hematology, The Affiliated Hospital of Qingdao University, Qingdao Shandong</p><p><img src="//html.hanspub.org/file/62-1571688x5_hanspub.png" /></p><p>Received: Nov. 2<sup>nd</sup>, 2020; accepted: Nov. 23<sup>rd</sup>, 2020; published: Nov. 30<sup>th</sup>, 2020</p><p><img src="//html.hanspub.org/file/62-1571688x6_hanspub.png" /></p></sec><sec id="s4"><title>ABSTRACT</title><p>Objective: To observe the clinical efficacy and safety of ibrutinib single drug regimen and CHOP regimen in the treatment of primary chronic lymphocytic leukemia. Methods: A retrospective analysis was performed on 48 newly treated patients with chronic lymphocytic leukemia who were treated in the hematology department of Qingdao University Hospital from March 2014 to March 2020. According to different treatment regiments, they were divided into ibrutinib group (30 cases) and CHOP group (18 cases). The clinical efficacy and adverse reactions of treatment regiments of the two groups were compared. Results: A total of 48 patients were included in this study. The results showed that the total effective rate (0RR) of the ibrutinib group was higher than that of the CHOP group (93.33% vs 40.00%), P = 0.009. The 1-year progression-free survival (PFS) rate in the ibrutinib group was significantly higher than that in CHOP group (80.00% vs 33.33%), and the difference was statistically significant (P = 0.025). 1-year overall survival (OS) was 96.67% in the ibrutinib group, and 63.33% in CHOP group, with statistically significant differences (P = 0.003). Among patients treated with ibrutinib, 36.67% had adverse events, including bleeding, atrial fibrillation, diarrhea, infection, etc. Adverse reactions, including neutropenia, anemia, bleeding, and vomiting, occurred in 53.33% of patients treated with CHOP. Conclusion: Ibrutinib can achieve higher remission rate and prolong progression free survival time in newly diagnosed patients with chronic lymphoblastic leukemia. The adverse reactions are mostly grade I - II, which is more tolerable than traditional chemotherapy.</p><p>Keywords:Brutinib, CHOP, Chronic Lymphocytic Leukemia, Effectiveness, Security</p><disp-formula id="hanspub.38949-formula49"><graphic xlink:href="//html.hanspub.org/file/62-1571688x7_hanspub.png"  xlink:type="simple"/></disp-formula><p>Copyright &#169; 2020 by author(s) and Hans Publishers Inc.</p><p>This work is licensed under the Creative Commons Attribution International License (CC BY 4.0).</p><p>http://creativecommons.org/licenses/by/4.0/</p><p><img src="//html.hanspub.org/file/62-1571688x8_hanspub.png" /> <img src="//html.hanspub.org/file/62-1571688x9_hanspub.png" /></p></sec><sec id="s5"><title>1. 引言</title><p>慢性淋巴细胞白血病(Chronic Lymphocytic Leukemia, CLL)是一种成熟B淋巴细胞的恶性克隆增殖性疾病，临床上主要表现为外周血中淋巴细胞计数增多，肝脾及淋巴结肿大，晚期可表现为骨髓进行性衰竭(贫血、血小板计数减少等)，是西方国家常见的B细胞恶性肿瘤之一；每年发病率在4~10/10万之间 [<xref ref-type="bibr" rid="hanspub.38949-ref1">1</xref>] [<xref ref-type="bibr" rid="hanspub.38949-ref2">2</xref>] [<xref ref-type="bibr" rid="hanspub.38949-ref3">3</xref>] [<xref ref-type="bibr" rid="hanspub.38949-ref4">4</xref>]，男性CLL发病率几乎是女性的两倍，且CLL发病率随年龄增加，CLL发病率在我国也逐年增加。虽然CLL通常表现为惰性病程，但就目前治疗手段而言，它在很大程度上仍然是不可治愈的疾病，且预后具有异质性，对于具有高危细胞遗传学因素的患者，常无法获得持久缓解 [<xref ref-type="bibr" rid="hanspub.38949-ref5">5</xref>]。化学免疫疗法在疾病的治疗过程中也取得一定的疗效，但因其毒副作用，在老年及一般状况较差患者中的应用受到一定限制。通过对CLL发病机制的研究发现，布鲁顿酪氨酸激酶(Bruton tyrosine kinase, BTK)是B细胞受体信号转导的关键成分，被认为是慢性淋巴细胞白血病发病机制的重要驱动因素 [<xref ref-type="bibr" rid="hanspub.38949-ref6">6</xref>] [<xref ref-type="bibr" rid="hanspub.38949-ref7">7</xref>] [<xref ref-type="bibr" rid="hanspub.38949-ref8">8</xref>]；伊布替尼是一种活性高、选择性不可逆的BTK抑制剂，随着B细胞受体通路抑制剂伊布替尼的出现，使CLL的治疗取得新的进展。多项研究 [<xref ref-type="bibr" rid="hanspub.38949-ref9">9</xref>] [<xref ref-type="bibr" rid="hanspub.38949-ref10">10</xref>] [<xref ref-type="bibr" rid="hanspub.38949-ref11">11</xref>] 表明伊布替尼在治疗慢性淋巴细胞白血病中具有良好的疗效，可提高患者的缓解率及无进展生存期，且具有良好的耐受性，NCCN指南也推荐伊布替尼作为CLL患者的一线治疗方案。由于伊布替尼上市不久且价格昂贵，既往我院CLL患者多用CHOP方案治疗，所以本研究回顾性分析伊布替尼单药治疗与CHOP方案治疗初治慢性淋巴细胞白血病的临床疗效及不良反应。</p></sec><sec id="s6"><title>2. 资料与方法</title><sec id="s6_1"><title>2.1. 研究对象</title><p>回顾性分析2014年03月至2020年03月就诊于我院的初治慢性淋巴细胞白血病患者，纳入标准：① 根据CLL诊断标准 [<xref ref-type="bibr" rid="hanspub.38949-ref12">12</xref>] 确诊为慢性淋巴细胞白血病；② 具备治疗指征 [<xref ref-type="bibr" rid="hanspub.38949-ref12">12</xref>] 且治疗前未接受过其他治疗；③ 无严重心脏疾病及肝肾功能损害；根据纳入标准，共有48例初治CLL患者入围，根据治疗方案不同，将其分为伊布替尼组及CHOP组2组。本次研究已获得医院医学伦理委员会的批准。(具体资料见表1)。</p><table-wrap id="table1" ><label><xref ref-type="table" rid="table1">Table 1</xref></label><caption><title> Basic clinical characteristics of the two groups of patient</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >项目</th><th align="center" valign="middle" >伊布替尼组 (n = 30)</th><th align="center" valign="middle" >CHOP组 (n = 18)</th><th align="center" valign="middle" >χ<sup>2</sup>值</th><th align="center" valign="middle" >P</th></tr></thead><tr><td align="center" valign="middle" >性别</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" >0.024</td><td align="center" valign="middle" >0.878<sup> </sup></td></tr><tr><td align="center" valign="middle" >男</td><td align="center" valign="middle" >19 (63.33%)</td><td align="center" valign="middle" >11 (61.11%)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >女</td><td align="center" valign="middle" >11 (36.67%)</td><td align="center" valign="middle" >7 (38.89%)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >年龄</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" >0.058</td><td align="center" valign="middle" >0.809</td></tr><tr><td align="center" valign="middle" >&gt;65岁</td><td align="center" valign="middle" >21 (70.00%)</td><td align="center" valign="middle" >12 (66.67%)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >&lt;65岁</td><td align="center" valign="middle" >9 (30.00%)</td><td align="center" valign="middle" >6 (33.33%)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >Binet分期<sup> </sup></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" >0.366</td><td align="center" valign="middle" >0.833</td></tr><tr><td align="center" valign="middle" >A期</td><td align="center" valign="middle" >9 (30.00%)</td><td align="center" valign="middle" >4 (22.22%)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >B期</td><td align="center" valign="middle" >8 (26.67%)</td><td align="center" valign="middle" >5 (27.78%)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >C期</td><td align="center" valign="middle" >13 (43.33%)</td><td align="center" valign="middle" >9 (50.00%)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >Rai分期</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" >0.392</td><td align="center" valign="middle" >0.983<sup> </sup></td></tr><tr><td align="center" valign="middle" >0期</td><td align="center" valign="middle" >6 (20.00%)</td><td align="center" valign="middle" >4 (22.22%)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >I期</td><td align="center" valign="middle" >5 (16.67%)</td><td align="center" valign="middle" >3 (16.67%)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >II期</td><td align="center" valign="middle" >9 (30.00%)</td><td align="center" valign="middle" >5 (27.78%)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >III期</td><td align="center" valign="middle" >7 (23.33%)</td><td align="center" valign="middle" >5 (27.78%)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >IV期</td><td align="center" valign="middle" >3 (10.00%)</td><td align="center" valign="middle" >3 (16.67%)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >TP53状态</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" >0.019</td><td align="center" valign="middle" >0.891</td></tr><tr><td align="center" valign="middle" >突变</td><td align="center" valign="middle" >9 (37.50%)</td><td align="center" valign="middle" >4 (40.00%)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >未突变</td><td align="center" valign="middle" >15 (62.50%)</td><td align="center" valign="middle" >6 (60.00%)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >IGHV状态</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" >0.002</td><td align="center" valign="middle" >0.961</td></tr><tr><td align="center" valign="middle" >突变</td><td align="center" valign="middle" >7 (29.17%)</td><td align="center" valign="middle" >3 (30.00%)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >未突变</td><td align="center" valign="middle" >17 (70.83%)</td><td align="center" valign="middle" >7 (70.00%)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >del (17p)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" >0.407</td><td align="center" valign="middle" >0.704</td></tr><tr><td align="center" valign="middle" >是</td><td align="center" valign="middle" >10 (41.67%)</td><td align="center" valign="middle" >3 (30.00%)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >否</td><td align="center" valign="middle" >14 (58.33%)</td><td align="center" valign="middle" >7 (70.00%)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr></tbody></table></table-wrap><p>表1. 2组患者的临床基本特征</p></sec><sec id="s6_2"><title>2.2. 治疗方案</title><p>伊布替尼组：伊布替尼420 mg/次，每日1次口服；CHOP组：环磷酰胺0.75 g/m<sup>2</sup>∙d，静脉滴注d1，表阿霉素50 mg/m<sup>2</sup>∙d，静脉滴注d1，长春地辛2.8 mg/m<sup>2</sup>∙d，静脉滴注d1，强的松100 mg∙d口服d1-5；2周检测血常规、肝肾功及监测不良反应；当出现粒细胞缺乏症时，给予刺激造血，必要时给予广谱抗生素抗感染等对症支持治疗；当出现严重贫血、血小板减少或出血等情况时，给予成分输血支持治疗。</p></sec><sec id="s6_3"><title>2.3. 疗效评价标准</title><p>本研究的临床疗效评价标准参考CLL 2018年版的IWCLL疗效标准 [<xref ref-type="bibr" rid="hanspub.38949-ref13">13</xref>]，具体为：完全缓解(complete remission, CR)、部分缓解(partial remission, PR)、疾病进展(progressive disease, PD)，总有效率(overall response rate, ORR) = CR + PR，评估患者的完全缓解率、部分缓解率、疾病进展率、总有效率以及随访1年时的无进展生存率(progression-free survival, PFS)、总生存率(overall survival, OS)，根据临床疗效评价标准以治疗过程中的最佳疗效进行疗效评估。</p></sec><sec id="s6_4"><title>2.4. 随访</title><p>随访时间从疾病确诊之日起，至2020年3月31日止。随访资料来源于患者的门诊、住院病历资料及电话随访记录。</p></sec><sec id="s6_5"><title>2.5. 统计学方法</title><p>统计学方法采取为SPSS22.0软件包进行统计学分析，率的比较采用卡方检验和Fisher确切概率法，生存分析采用Kaplan-Meier法，采用log-rank检验进行组间比较，P &lt; 0.05为差异有统计学意义。</p></sec></sec><sec id="s7"><title>3. 结果</title><sec id="s7_1"><title>3.1. 两组疗效比较</title><p>伊布替尼组共30例，其中7例(23.33%)患者达到完全缓解(CR)高于CHOP组(1例，6.67%)差异无统计学意义(P = 0.229)；伊布替尼组21例(70.00%)患者达到部分缓解(PR)，CHOP组PR率为33.33%，差异无统计学意义(P = 0.361)；伊布替尼组2例(3.33%)出现疾病进展，CHOP组共7例(30.00%)患者出现疾病进展，差异具有统计学意义(P = 0.009)，(见表2)。</p><table-wrap id="table2" ><label><xref ref-type="table" rid="table2">Table 2</xref></label><caption><title> Curative effect analysis of the two groups (n, %</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >组别</th><th align="center" valign="middle" >n</th><th align="center" valign="middle" >CR</th><th align="center" valign="middle" >PR</th><th align="center" valign="middle" >PD</th></tr></thead><tr><td align="center" valign="middle" >伊布替尼组</td><td align="center" valign="middle" >30</td><td align="center" valign="middle" >7 (23.33)</td><td align="center" valign="middle" >21 (70.00)</td><td align="center" valign="middle" >2 (3.33)</td></tr><tr><td align="center" valign="middle" >CHOP组</td><td align="center" valign="middle" >18</td><td align="center" valign="middle" >1 (6.67)</td><td align="center" valign="middle" >10 (33.33)</td><td align="center" valign="middle" >7 (30.00)</td></tr><tr><td align="center" valign="middle" >χ<sup>2</sup></td><td align="center" valign="middle" ></td><td align="center" valign="middle" >2.560</td><td align="center" valign="middle" >1.026</td><td align="center" valign="middle" >7.667</td></tr><tr><td align="center" valign="middle" >p</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >0.229</td><td align="center" valign="middle" >0.361</td><td align="center" valign="middle" >0.009</td></tr></tbody></table></table-wrap><p>表2. 两组疗效分析(n, %)</p></sec><sec id="s7_2"><title>3.2. 两组生存比较</title><p>伊布替尼组1例患者在随访期内因疾病进展出现严重肺部感染死亡，CHOP组共7例患者死于疾病进展或并发症；伊布替尼组总有效率(ORR)为93.33%，CHOP组ORR为40%，差异有统计学意义(P &lt; 0.05)；伊布替尼组1年无进展生存(PFS)率为80%高于CHOP组(33.33%)，差异有统计学意义(P &lt; 0.05)；伊布替尼组1年生存率(OS)为96.67%高于CHOP组(OS率63.33%)，差异均有统计学意义(P &lt; 0.05)，(见表3及图1)。</p><table-wrap id="table3" ><label><xref ref-type="table" rid="table3">Table 3</xref></label><caption><title> Survival analysis of the two groups (n, %</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >组别</th><th align="center" valign="middle" >n</th><th align="center" valign="middle" >0RR</th><th align="center" valign="middle" >1年PFS</th><th align="center" valign="middle" >1年OS</th></tr></thead><tr><td align="center" valign="middle" >伊布替尼组</td><td align="center" valign="middle" >30</td><td align="center" valign="middle" >28 (93.33)</td><td align="center" valign="middle" >24 (80.00)</td><td align="center" valign="middle" >29 (96.67)</td></tr><tr><td align="center" valign="middle" >CHOP组</td><td align="center" valign="middle" >18</td><td align="center" valign="middle" >11 (40.00)</td><td align="center" valign="middle" >8 (33.33)</td><td align="center" valign="middle" >11 (63.33)</td></tr><tr><td align="center" valign="middle" >χ<sup>2</sup></td><td align="center" valign="middle" ></td><td align="center" valign="middle" >7.667</td><td align="center" valign="middle" >6.400</td><td align="center" valign="middle" >10.240</td></tr><tr><td align="center" valign="middle" >p</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >0.009</td><td align="center" valign="middle" >0.025</td><td align="center" valign="middle" >0.003</td></tr></tbody></table></table-wrap><p>表3. 两组的生存分析(n, %)</p><p>图1. 伊布替尼组与CHOP组之间1年总生存率(OS)的比较</p></sec><sec id="s7_3"><title>3.3. 不良反应比较</title><p>不良反应分级参照2017年美国卫生及公共服务部常见不良反应评价标准(CTCAE)。伊布替尼组最常见的不良反应为出血，发生率为20.00%，多表现为皮肤及粘膜的瘀点瘀斑，多为1~2级，无大出血事件发生，治疗过程中未减少药物用量或停药；CHOP组1~2级出血事件的发生率为33.33%，仅1例患者出现3级出血事件，给予止血、成分输血治疗后好转；伊布替尼组有1例患者出现新发房颤，发生率为3.33%，给予复律及控制心率治疗心悸症状缓解，中间未停药。CHOP组感染的发生率(1~2级43.33%，≥3级13.33%)高于伊布替尼组(1~2级感染13.33%，3~4级感染，6.67%)，给予粒细胞刺激因子或抗感染治疗后好转，所有患者均未停药或减少药物剂量；伊布替尼组有2例患者出现消化道症状，表现为腹泻，给予对症治疗后好转，其发生率远远低于CHOP组(6.67% VS 30%)，(见表4)。</p><table-wrap id="table4" ><label><xref ref-type="table" rid="table4">Table 4</xref></label><caption><title> Analysis of adverse reactions in two groups (n, %</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >组别</th><th align="center" valign="middle" >n</th><th align="center" valign="middle" >1~2级出血</th><th align="center" valign="middle" >≥3级出血</th><th align="center" valign="middle" >1~2级感染</th><th align="center" valign="middle" >≥3级感染</th><th align="center" valign="middle" >房颤</th><th align="center" valign="middle" >皮疹</th><th align="center" valign="middle" >肝肾损害</th><th align="center" valign="middle" >消化道反应</th></tr></thead><tr><td align="center" valign="middle" >伊布替尼组</td><td align="center" valign="middle" >30</td><td align="center" valign="middle" >4 (20.00)</td><td align="center" valign="middle" >0</td><td align="center" valign="middle" >4 (13.33)</td><td align="center" valign="middle" >2 (6.67)</td><td align="center" valign="middle" >1 (3.33)</td><td align="center" valign="middle" >2 (6.67)</td><td align="center" valign="middle" >0</td><td align="center" valign="middle" >2 (6.67)</td></tr><tr><td align="center" valign="middle" >CHOP组</td><td align="center" valign="middle" >18</td><td align="center" valign="middle" >6 (33.33)</td><td align="center" valign="middle" >1 (3.33)</td><td align="center" valign="middle" >4 (43.33)</td><td align="center" valign="middle" >4 (13.33)</td><td align="center" valign="middle" >0</td><td align="center" valign="middle" >0</td><td align="center" valign="middle" >5 (16.67)</td><td align="center" valign="middle" >9 (30.00)</td></tr><tr><td align="center" valign="middle" >χ<sup>2</sup></td><td align="center" valign="middle" ></td><td align="center" valign="middle" >2.728</td><td align="center" valign="middle" >1.702</td><td align="center" valign="middle" >0.640</td><td align="center" valign="middle" >2.489</td><td align="center" valign="middle" >0.613</td><td align="center" valign="middle" >1.252</td><td align="center" valign="middle" >9.902</td><td align="center" valign="middle" >11.959</td></tr><tr><td align="center" valign="middle" >p</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >0.145</td><td align="center" valign="middle" >0.375</td><td align="center" valign="middle" >0.451</td><td align="center" valign="middle" >0.179</td><td align="center" valign="middle" >1.000</td><td align="center" valign="middle" >0.521</td><td align="center" valign="middle" >0.005</td><td align="center" valign="middle" >0.001</td></tr></tbody></table></table-wrap><p>表4. 两组不良反应分析(n, %)</p><p>注：CTCAE分为5级：1级无症状，不需干预；2级采取非紧急的医疗干预；3级有症状，药物不能完全控制，需要紧急处理或需要起搏器、消融等控制；4级危及生命，需要紧急治疗；5级死亡。</p></sec></sec><sec id="s8"><title>4. 讨论</title><p>慢性淋巴细胞白血病(Chronic Lymphocytic Leukemia, CLL)是一种成熟B淋巴细胞的克隆增殖性疾病；2020年NCCN指南推荐，对于初诊的CLL患者无论其年龄、体能状态、有无并发症及有无del(17p)/TP53基因突变均优先推荐伊布替尼治疗；但对于年龄 &lt; 65岁、身体状态良好伴有IGHV突变的患者，相较于利妥昔单抗联合氟达拉滨和环磷酰胺(FCR)方案，伊布替尼的PFS无明显优势，所以对于此类患者，FCR方案仍然是合适的一线治疗方案 [<xref ref-type="bibr" rid="hanspub.38949-ref14">14</xref>]。在一项Ⅱ期临床研究中 [<xref ref-type="bibr" rid="hanspub.38949-ref9">9</xref>] [<xref ref-type="bibr" rid="hanspub.38949-ref10">10</xref>]，用伊布替尼每日420或840 mg的剂量已经治疗85例复发/难治性CLL/SLL患者和31例初治CLL/SLL老年患者，26个月无进展生存期分别达到了75%和96%，总生存率达到了83%和96%，显示出良好的治疗反应；一项RESONATE-2临床试验 [<xref ref-type="bibr" rid="hanspub.38949-ref11">11</xref>] 对比了265例初治CLL患者应用伊布替尼和苯丁酸氮芥的疗效，结果显示伊布替尼组ORR率、PFS率明显高于苯丁酸氮芥组(ORR：92% vs 36%，2年PFS：89% vs 34%)。美国的一项研究中 [<xref ref-type="bibr" rid="hanspub.38949-ref15">15</xref>]，35例存在TP53基因异常的初治CLL患者接受伊布替尼单药治疗，5年预计PFS率74.4%，5年预计OS率85.3%，改善了该类患者的预后。</p><p>慢性淋巴细胞白血病细胞的增殖和存活依赖于微环境因子，尤其是在组织内的CLL细胞表现出明显的B细胞受体(BCR)和NF-κB通路的激活 [<xref ref-type="bibr" rid="hanspub.38949-ref16">16</xref>]；布鲁顿酪氨酸激酶(BTK)是Tec激酶家族的成员之一，它可以通过激活BCR促进细胞内钙的释放和激活NF-κB信号通路，促进细胞增殖。BTK在CLL细胞中的表达明显高于正常B细胞 [<xref ref-type="bibr" rid="hanspub.38949-ref17">17</xref>]，在B细胞恶性肿瘤中，抑制BTK可减少肿瘤细胞的增殖，并抑制肿瘤细胞向促进其生长的微环境黏附和迁移 [<xref ref-type="bibr" rid="hanspub.38949-ref18">18</xref>]。伊布替尼是一种非选择性不可逆的BTK抑制剂，与BTK活性位点Cys-481半胱氨酸残基不可逆的结合，抑制BTK信号通路，抑制B细胞活动，治疗各种B细胞性肿瘤。2014年被美国FDA批准用于治疗CLL，在2016年用于CLL的一线治疗。</p><p>在本研究中我们观察了48例初诊慢性淋巴细胞白血病患者，结果显示，伊布替尼组完全缓解及部分缓解人数虽多余CHOP方案组，但差异无统计学意义，考虑与本研究病例数较少有关；伊布替尼组总有效率(ORR)、1年无进展生存(PFS)率、1年总生存率(OS)均于CHOP组，差异均有统计学意义，说明伊布替尼单药治疗较CHOP方案治疗可以达到更好的缓解率，延长患者生存期，并改善患者预后。</p><p>传统化学疗法常因其生物学毒性产生骨髓抑制出现感染、贫血、出血及消化道不良反应；在伊布替尼治疗过程中常出现不同程度的不良反应，主要包括出血、感染、房颤、腹泻、皮疹等 [<xref ref-type="bibr" rid="hanspub.38949-ref19">19</xref>] [<xref ref-type="bibr" rid="hanspub.38949-ref20">20</xref>] [<xref ref-type="bibr" rid="hanspub.38949-ref21">21</xref>]。在本研究中，伊布替尼组最常见的不良反应为出血，多表现为皮肤及粘膜的瘀点瘀斑，多为1~2级，较CHOP组发生率低，1~2级出血多无需停药，必要时给予对症处理及保护措施，预防大出血事件发生，当发生大出血事件时建议停药并输注血小板；两组治疗过程中均出现不同程度感染，以肺部感染最常见，CHOP组感染发生率高于伊布替尼组，当发生任何程度感染时均应系统筛查，必要时给予积极抗感染治疗；伊布替尼组有1例患者出现新发房颤，房颤的发生率在开始用药的前6个月内最高 [<xref ref-type="bibr" rid="hanspub.38949-ref22">22</xref>]，对于1级和2级房颤，多无需停止伊布替尼治疗，对于3级及以上的房颤患者，应停止伊布替尼治疗，选择伊布替尼替代方案；一般不建议停药，因为停药会减少患者的生存期，可给予β受体阻滞剂控制心率，因抗心律失常药物与伊布替尼可能存在相互作用，首选电复律或射频消融，必要时行抗凝治疗；两组常见的消化系统不良反应主要表现为恶心、呕吐、腹泻等，患者多可耐受，给予对症治疗后可缓解；研究提示，与传统化疗方案相比，伊布替尼方案用药方便且具有更好的耐受性，可以减少患者住院次数，改善患者的生活质量。</p><p>综上所述，本研究初步结果显示伊布替尼单药治疗较CHOP方案化疗治疗慢性淋巴细胞白血病可以达到较好的缓解率，延长生存时间，具有更好的耐受性，是治疗初治慢性淋巴细胞白血病的一线治疗方案。但本研究为单中心回顾性分析，且纳入的样本量较少，结论仍需多中心、前瞻性随机对照研究进一步论证。</p></sec><sec id="s9"><title>文章引用</title><p>段春英,吴少玲,袁海峰,宋 峤,曹 正. 伊布替尼单药方案与CHOP方案治疗慢性淋巴细胞白血病的临床疗效观察Clinical Efficacy of Ibrutinib Monotherapy and CHOP in the Treatment of Chronic Lymphocytic Leukemia[J]. 临床医学进展, 2020, 10(11): 2819-2826. https://doi.org/10.12677/ACM.2020.1011428</p></sec><sec id="s10"><title>参考文献</title></sec></body><back><ref-list><title>References</title><ref id="hanspub.38949-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Call, T.G., Norman, A.D., Hanson, C.A., et al. (2014) Incidence of Chronic Lymphocytic Leukemia and High-Count Monoclonal B-Cell Lymphocytosis Using the 2008 Guidelines. Cancer, 120, 2000-2005.  
&lt;br&gt;https://doi.org/10.1002/cncr.28690</mixed-citation></ref><ref id="hanspub.38949-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">Abrisqueta, P., Pereira, A., Rozman, C., et al. (2009) Improving Survival in Patients with Chronic Lymphocytic Leukemia (1980-2008): The Hospital Clinic of Barcelona Experience. Blood, 114, 2044-2050.  
&lt;br&gt;https://doi.org/10.1182/blood-2009-04-214346</mixed-citation></ref><ref id="hanspub.38949-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">Brenner, H., Gondos, A. and Pulte, D. (2008) Trends in Long-Term Survival of Patients with Chronic Lymphocytic Leukemia from the 1980s to the Early 21st Century. Blood, 111, 4916-4921.  
&lt;br&gt;https://doi.org/10.1182/blood-2007-12-129379</mixed-citation></ref><ref id="hanspub.38949-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">Seftel, M.D., Demers, A.A., Banerji, V., et al. (2009) High Incidence of Chronic Lymphocytic Leukemia (CLL) Diagnosed by Immunophenotyping: A Population-Based Canadian Cohort. Leukemia Research, 33, 1463-1468.  
&lt;br&gt;https://doi.org/10.1016/j.leukres.2009.06.013</mixed-citation></ref><ref id="hanspub.38949-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">付小艳, 牛挺. 慢性淋巴细胞白血病/小淋巴细胞淋巴瘤NCCN新版指南(2019.V3)解读[J]. 华西医学, 2019, 34(4): 355-362.</mixed-citation></ref><ref id="hanspub.38949-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Satterthwaite, A.B. and Witte, O.N. (2000) The Role of Bruton’s Tyrosine Kinase in B-Cell Development and Function: A Genetic Perspective. Immunological Reviews, 175, 120-127. &lt;br&gt;https://doi.org/10.1111/j.1600-065X.2000.imr017504.x</mixed-citation></ref><ref id="hanspub.38949-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">de Gorter, D.J.J., Beuling, E.A., Kersseboom, R., et al. (2007) Bruton’s Tyrosine Kinase and Phospholipase C Gamma 2 Mediate Chemokine-Controlled B Cell Migration and Homing. Immunity, 26, 93-104.  
&lt;br&gt;https://doi.org/10.1016/j.immuni.2006.11.012</mixed-citation></ref><ref id="hanspub.38949-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">Ortolano, S., Hwang, I.Y., Han, S.B., et al. (2006) Roles for Phosphoinositide 3-Kinases, Bruton’s Tyrosine Kinase, and Jun Kinases in B Lymphocyte Chemotaxis and Homing. European Journal of Immunology, 36, 1285-1295.  
&lt;br&gt;https://doi.org/10.1002/eji.200535799</mixed-citation></ref><ref id="hanspub.38949-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">Byrd, J.C., Furman, R.R., Coutre, S.E., et al. (2013) Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia. New England Journal of Medicine, 369, 32-42. &lt;br&gt;https://doi.org/10.1056/NEJMoa1215637</mixed-citation></ref><ref id="hanspub.38949-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">O’Brien, S., Furman, R.R., Coutre, S.E., et al. (2014) Ibrutinib as Initial Therapy for Elderly Patients with Chronic Lymphocytic Leukaemia or Small Lymphocytic Lymphoma: An Open-Label, Multicentre, phase1b/2trial. The Lancet Oncology, 15, 48-58. &lt;br&gt;https://doi.org/10.1016/S1470-2045(13)70513-8</mixed-citation></ref><ref id="hanspub.38949-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">Burger, J.A., Tedeschi, A., Barr, P.M., et al. (2015) Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia. New England Journal of Medicine, 373, 2425-2437. &lt;br&gt;https://doi.org/10.1056/NEJMoa1509388</mixed-citation></ref><ref id="hanspub.38949-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">中华医学会血液学分会白血病淋巴瘤学组, 中国抗癌协会血液肿瘤专业委员会, 中国慢性淋巴细胞白血病工作组. 中国慢性淋巴细胞白血病/小淋巴细胞淋巴瘤的诊断与治疗指南(2018年版) [J]. 中华血液学杂志, 2018, 39(5): 353-358.</mixed-citation></ref><ref id="hanspub.38949-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">Hallek, M., Cheson, B.D., Catovsky, D., et al. (2018) iwCLL Guidelines for Diagnosis, Indications for Treatment, Response Assessment, and Supportive Management of CLL. Blood, 131, 2745-2760.  
&lt;br&gt;https://doi.org/10.1182/blood-2017-09-806398</mixed-citation></ref><ref id="hanspub.38949-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">李建勇, 夏奕, 徐卫. 新药时代慢性淋巴细胞白血病的治疗选择[J]. 山东大学学报(医学版), 2019, 57(7): 21-30.</mixed-citation></ref><ref id="hanspub.38949-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">Ahn, I.E., Farooqui, M.Z.H., Tian, X., et al. (2018) Depth and Durability of Response to Ibrutinib in CLL: 5-Year Follow-Up of a Phase 2 Study. Blood, 131, 2357-2366. &lt;br&gt;https://doi.org/10.1182/blood-2017-12-820910</mixed-citation></ref><ref id="hanspub.38949-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">Buggy, J.J. and Elias, L. (2012) Bruton Tyrosine Kinase (BTK) and Its Role in B-Cell Malignancy. International Reviews of Immunology, 31, 119-132. &lt;br&gt;https://doi.org/10.3109/08830185.2012.664797</mixed-citation></ref><ref id="hanspub.38949-ref17"><label>17</label><mixed-citation publication-type="other" xlink:type="simple">Herman, S.E., Gordon, A.L., Hertlein, E., et al. (2011) Bruton Tyrosine Kinase Represents a Promising Therapeutic Target for Treatment of Chronic Lymphocytic Leukemia and Is Effectively Targeted by PCI-32765. Blood, 117, 6287-6296. &lt;br&gt;https://doi.org/10.1182/blood-2011-01-328484</mixed-citation></ref><ref id="hanspub.38949-ref18"><label>18</label><mixed-citation publication-type="other" xlink:type="simple">Herman, S.E., Mustafa, R.Z., Gyamfi, J.A., et al. (2014) Ibrutinib Inhibits BCR and NF-kappaB Signaling and Reduces Tumor Proliferation in Tissue-Resident Cells of Patients with CLL. Blood, 123, 3286-3295.  
&lt;br&gt;https://doi.org/10.1182/blood-2014-02-548610</mixed-citation></ref><ref id="hanspub.38949-ref19"><label>19</label><mixed-citation publication-type="other" xlink:type="simple">UK CLL Forum (2016) Ibrutinib for Relapsed/Refractory Chronic Lymphocytic Leukemia: A UK and Ireland Analysis of Outcomes in 315 Patients. Haematologica, 101, 1563-1572. &lt;br&gt;https://doi.org/10.3324/haematol.2016.147900</mixed-citation></ref><ref id="hanspub.38949-ref20"><label>20</label><mixed-citation publication-type="other" xlink:type="simple">Coutre, S., Byrd, J., Hillmen, P., et al. (2019) Long-Term Safety of Single-Agent Ibrutinib in Patients with Chronic Lymphocytic Leukemia in 3 Pivotal Studies. Blood Advances, 3, 1799-1807.  
&lt;br&gt;https://doi.org/10.1182/bloodadvances.2018028761</mixed-citation></ref><ref id="hanspub.38949-ref21"><label>21</label><mixed-citation publication-type="other" xlink:type="simple">Burger, J., Barr, P., Robak, T., et al. (2020) Long-Term Efficacy and Safety of First-Line Ibrutinib Treatment for Patients with CLL/SLL: 5 Years of Follow-Up from the Phase 3 RESONATE-2 Study. Leukemia, 34, 787-798.  
&lt;br&gt;https://doi.org/10.1038/s41375-019-0602-x</mixed-citation></ref><ref id="hanspub.38949-ref22"><label>22</label><mixed-citation publication-type="other" xlink:type="simple">Lasica, M. and Chmr, T.C.J. (2020) Management of Ibrutinib Toxicities: A Practical Guide. Current Hematologic Malignancy Reports, 15, 177-186. &lt;br&gt;https://doi.org/10.1007/s11899-020-00576-3</mixed-citation></ref></ref-list></back></article>